Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBV A/B for BabyBIG Production in Volunteers With Existing Botulinum Immunity
NCT06112834Phase 2Completed
- Sponsor
- California Department of Public Health
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant botulinum vaccine A/B in botulism, sponsored by California Department of Public Health. Primary endpoint: Proportion of Subjects Achieving Equal to or Greater Than 4-Fold Increase in Neutralizing Antibody Concentration (NAC) at 4 weeks. Started Jul 2024; status: completed.
02
Drugs
recombinant botulinum vaccine A/B
03
Conditions
botulism
Beyond the preview
Go deeper on NCT06112834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112834.